Normalization in Human Glioma Tissue

Author(s):  
Ana Paula Santin Bertoni ◽  
Isabele Cristiana Iser ◽  
Rafael Paschoal de Campos ◽  
Márcia Rosangela Wink
Keyword(s):  
2018 ◽  
Vol 20 (suppl_6) ◽  
pp. vi253-vi253
Author(s):  
Pieter Wesseling ◽  
Andy Zhang ◽  
Jan de Munck ◽  
Niels Verburg ◽  
Philip de Witt Hamer ◽  
...  

1986 ◽  
pp. 495-499 ◽  
Author(s):  
Carol J. Wikstrand ◽  
Friedrich C. Grahmann ◽  
Rodney D. McComb ◽  
Darell D. Bigner

2019 ◽  
Vol 9 (6) ◽  
pp. 616-622
Author(s):  
Mo Wang ◽  
Shengqiang Jiang ◽  
Xu Zhang ◽  
Ruoyu Peng ◽  
Minghua Zhu ◽  
...  

Gliomas are the most common type of malignant brain tumors. Glioma diagnosis is not very effective, and there are few therapeutic biomarkers. The aims of this study were to detect Pokemon and its regulatory genes and explore the potential mechanism between them in glioma. The Fe3O4 nanoparticles identified using TEM were used to isolate cell and tissue RNA, qRT-PCR was used to detect Pokemon, survivin, and cyclin B1 mRNA expression. Western blotting was used to detect Pokemon, survivin, and cyclin B1 protein expression. Immunofluorescence and immunohistochemistry were used to detect Pokemon expression. CCK-8 assay, EdU staining, and TUNEL staining were used to assess cell viability and apoptosis. Pokémon was over-expressed in human glioma tissue and cells. In U251 cells, Pokemon knockdown significantly decreased survivin and cyclin B1 expression, cell viability, and Pokemon expression and increased apoptosis. Pokemon overexpression had an opposite effect. In addition, over-expressed Pokemon reversed these results. Overall, we found that Pokemon promotes tumorigenesis, and the potential mechanism might be related to the Pokemon-related genes survivin and cyclin B1.


2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii215-ii216
Author(s):  
Renee Hirte ◽  
Ian E Olson ◽  
Masum Rahman ◽  
Moustafa Mansour ◽  
Amanda Munoz Casabella ◽  
...  

Abstract Glioblastoma multiforme (GBM) is the most aggressive CNS neoplasm with a mere 15 month progression-free survival following current standards-of-care. Furthermore, conventional therapies have been effective, in part, by inducing a senescent-like phenotype in at least a proportion of glioma, as well as within the tumor-adjacent, healthy brain cells. Through an N-glyco-capture large-scale screening method, we were able to identify 25 genes exclusively overexpressed on glioma cell surfaces. Of those 25 targets, CD38 was an attractive target due to pre-existing FDA approved therapeutics. Recent studies have shown, however, that senescent cells, such as those induced via chemo- and radiotherapies, secrete a pro-inflammatory array of cytokines, known collectively as senescence associated secretory phenotype (SASP), that are capable of increasing CD38 expression in monocytes. CD38 functions as an ectoenzyme to convert extracellular NAD+ to nicotinamide (required for glioma cell salvage pathway NAD+ synthesis) and ADPR/cADPR (a cellular proliferation signal). To examine the effects of radiation on human glioma tissue, we performed reverse cyclase assays (RCA) on paired primary and recurrent human glioma tissue samples and found an increase in CD38 activity in post-irradiated tissues (recurrent glioma) compared to pre-irradiated (primary glioma). Through proliferation assays, we also found an increase in glioma cell growth following treatment with cADPR compared to untreated. Our results demonstrate that CD38 activity is tumorgenic, and furthermore that conventional chemo- and radiotherapies increase this CD38 activity. This indicates that treating CD38 with previously FDA approved therapeutics may provide hope for increasing progression free survival in our GBM patient population, and moreover emphasize the importance of leveraging novel large scale screening methods for identifying additional opportunities for treatment.


2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Selin Ekici ◽  
Benjamin B. Risk ◽  
Stewart G. Neill ◽  
Hui-Kuo Shu ◽  
Candace C. Fleischer

AbstractGliomas are one of the most common types of brain tumors. Given low survival and high treatment resistance rates, particularly for high grade gliomas, there is a need for specific biomarkers that can be used to stratify patients for therapy and monitor treatment response. Recent work has demonstrated that metabolic reprogramming, often mediated by inflammation, can lead to an upregulation of glutamine as an energy source for cancer cells. As a result, glutamine pathways are an emerging pharmacologic target. The goal of this pilot study was to characterize changes in glutamine metabolism and inflammation in human glioma samples and explore the use of glutamine as a potential biomarker. 1H high-resolution magic angle spinning nuclear magnetic resonance spectra were acquired from ex vivo glioma tissue (n = 16, grades II–IV) to quantify metabolite concentrations. Tumor inflammatory markers were quantified using electrochemiluminescence assays. Glutamate, glutathione, lactate, and alanine, as well as interleukin (IL)-1β and IL-8, increased significantly in samples from grade IV gliomas compared to grades II and III (p ≤ .05). Following dimension reduction of the inflammatory markers using probabilistic principal component analysis, we observed that glutamine, alanine, glutathione, and lactate were positively associated with the first inflammatory marker principal component. Our findings support the hypothesis that glutamine may be a key marker for glioma progression and indicate that inflammation is associated with changes in glutamine metabolism. These results motivate further in vivo investigation of glutamine as a biomarker for tumor progression and treatment response.


2019 ◽  
Vol 159 (3) ◽  
pp. 119-125 ◽  
Author(s):  
Feng Li ◽  
Chao Zhang ◽  
Guifang Zhang

Glioma, as one of the most aggressive tumors, is hardly cleaned by surgical removal, leading to a low survival rate. m6A is an internal modification in RNA and plays an important role in many kinds of cancers. In our study, we detected that the m6A level was decreased in glioma tissue, which might be caused by decreased METTL3 and increased FTO levels. We upregulated the m6A level in U251 cells by overexpressing METTL3. The results showed that a high level of m6A led to a reduced migration and proliferation ability, and vice versa. Finally, we performed a TUNEL assay and showed that m6A regulated cell proliferation by influencing apoptosis of U251 cells through regulating HSP90 expression.


1993 ◽  
Vol 119 (8) ◽  
pp. 493-496 ◽  
Author(s):  
Akira Hara ◽  
Noboru Sakai ◽  
Hiromu Yamada ◽  
Naoki Yoshimi ◽  
Takuji Tanaka ◽  
...  

2014 ◽  
Vol 275 (1-2) ◽  
pp. 35
Author(s):  
Lukas Bunse ◽  
Theresa Schumacher ◽  
Felix Sahm ◽  
Stefan Pusch ◽  
Iris Oezen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document